Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ERGO
Entia Biosciences
$0.00
$0.00
$0.00
N/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$10.70
$10.70
$3.95
$11.35
$292.42M2.38327,575 shs54 shs
Resverlogix Corp. stock logo
RVX
Resverlogix
C$0.06
C$0.06
C$0.05
C$0.16
C$16.33M0.7837,265 shs36,650 shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ERGO
Entia Biosciences
0.00%0.00%0.00%0.00%-50.00%
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.00%0.00%0.00%0.00%0.00%
Resverlogix Corp. stock logo
RVX
Resverlogix
0.00%+9.09%+9.09%-7.69%-60.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/AN/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ERGO
Entia Biosciences
N/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$937.80M0.31$1.97 per share5.43$3.40 per share3.15
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AC$0.00 per share132.50C($0.26) per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ERGO
Entia Biosciences
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$48.50M$1.776.05N/A5.17%66.00%15.67%N/A
Resverlogix Corp. stock logo
RVX
Resverlogix
-C$12.82M-C$0.05N/AN/AN/AN/A-37.10%5/9/2024 (Estimated)

Latest ERGO, HBP, BVXP, RVX, and FARN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/1/2024Q4 2023
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A-C$0.01-C$0.01-C$0.01N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ERGO
Entia Biosciences
N/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ERGO
Entia Biosciences
N/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.75
2.05
0.95
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A
0.11
0.04

Ownership

Institutional Ownership

CompanyInstitutional Ownership
ERGO
Entia Biosciences
N/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
54.10%
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A

Insider Ownership

CompanyInsider Ownership
ERGO
Entia Biosciences
28.30%
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
10.95%
Resverlogix Corp. stock logo
RVX
Resverlogix
43.19%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ERGO
Entia Biosciences
6N/AN/ANot Optionable
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
1,10027.33 million24.34 millionOptionable
Resverlogix Corp. stock logo
RVX
Resverlogix
19272.17 millionN/ANot Optionable

ERGO, HBP, BVXP, RVX, and FARN Headlines

SourceHeadline
Resverlogix Announces Change to Its Board of DirectorsResverlogix Announces Change to Its Board of Directors
finance.yahoo.com - February 21 at 8:02 PM
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalones Potential Therapeutic BenefitsResverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
finance.yahoo.com - January 11 at 10:03 AM
Closing Bell: Resverlogix Corp flat on Tuesday (RVX)Closing Bell: Resverlogix Corp flat on Tuesday (RVX)
theglobeandmail.com - January 4 at 6:16 PM
Resverlogix Corp. (RVX) Earnings Dates & ReportsResverlogix Corp. (RVX) Earnings Dates & Reports
investing.com - December 19 at 7:28 PM
Resverlogix Corp RVXCFResverlogix Corp RVXCF
morningstar.com - November 18 at 5:49 PM
Resverlogix Corp RVXResverlogix Corp RVX
morningstar.com - November 1 at 11:18 AM
Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)
theglobeandmail.com - October 18 at 7:46 AM
Resverlogix Corp.: Resverlogix Publishes on Apabetalones Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyResverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
finanznachrichten.de - October 4 at 10:11 AM
Resverlogix Publishes on Apabetalones Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyResverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
finance.yahoo.com - October 4 at 10:11 AM
Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsightAtherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight
finance.yahoo.com - September 26 at 8:50 PM
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 DiabetesResverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
finance.yahoo.com - August 29 at 10:13 AM
Closing Bell: Resverlogix Corp up on Wednesday (RVX)Closing Bell: Resverlogix Corp up on Wednesday (RVX)
theglobeandmail.com - August 24 at 3:35 PM
Closing Bell: Resverlogix Corp flat on Monday (RVX)Closing Bell: Resverlogix Corp flat on Monday (RVX)
theglobeandmail.com - August 14 at 10:02 PM
Closing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A)Closing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A)
theglobeandmail.com - July 12 at 7:21 AM
Resverlogix Announces Warrant Repricing and One-Year ExtensionResverlogix Announces Warrant Repricing and One-Year Extension
finance.yahoo.com - June 29 at 11:09 PM
Resverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of ShareholdersResverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders
finanznachrichten.de - June 20 at 7:31 PM
Resverlogix Announces Voting Results from the 2023 Meeting of ShareholdersResverlogix Announces Voting Results from the 2023 Meeting of Shareholders
finance.yahoo.com - June 20 at 7:31 PM
Resverlogix Announces New Insights into the Mechanism of Apabetalones Cardioprotective Benefit in Chronic Kidney Disease PatientsResverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
finance.yahoo.com - June 12 at 6:42 PM
Canadian Investment Regulatory Organization Trading Halt - RVX.WT.ACanadian Investment Regulatory Organization Trading Halt - RVX.WT.A
finance.yahoo.com - June 7 at 1:32 PM
Closing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A)Closing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A)
theglobeandmail.com - June 6 at 10:49 AM
Closing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A)Closing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A)
theglobeandmail.com - May 25 at 12:52 AM
CBOE RUSSELL 2000 VOLATILITY IN (^RVX)CBOE RUSSELL 2000 VOLATILITY IN (^RVX)
finance.yahoo.com - May 18 at 12:38 AM
Bromodomain Containing Protein 2 Market is Likely to Upsurge at ... - StreetBuzzBromodomain Containing Protein 2 Market is Likely to Upsurge at ... - StreetBuzz
news.google.com - May 13 at 3:47 PM
Resverlogix : MD&A Q1 2023 - Marketscreener.comResverlogix : MD&A Q1 2023 - Marketscreener.com
news.google.com - May 12 at 3:50 PM

Media Sentiment Over Time

Company Descriptions

Entia Biosciences

OTCMKTS:ERGO
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.
Huttig Building Products logo

Huttig Building Products

NASDAQ:HBP
Huttig Building Products, Inc., together with its subsidiaries, distributes millwork, building materials, and wood products for new residential construction, in-home improvement, remodeling, and repair works in the United States. The company offers various millwork products, including exterior and interior doors, pre-hung and factory finished door units, windows, patio doors, mouldings, frames, stair parts, and columns under the Therma-Tru, Masonite, Woodgrain, HB&G, Simpson Door, Final Frame, BrasPine, Arauco, Windsor Windows, and Rogue Valley Door brands. It also provides general building products, such as fasteners and connectors, roofing, siding, insulation, flashing, housewrap, decking, railings, and other miscellaneous building products under the Huttig-Grip, Louisiana-Pacific, Simpson Strong-Tie, TimberTech, AZEK, RDI, GAF Roofing, Maibec, Knauf, GCP Technologies, Fiberon, Alpha Protech, MFM, Lomanco, and Fortifiber brands. In addition, the company offers wood products comprising engineered wood products used in floor systems, wood panels, and lumber; and value-added services, such as floor system take-offs, cut-to-length packages and just-in-time, and cross-dock delivery under the Louisiana-Pacific and Rosboro brands. It markets and sells its products through a network of 25 wholesale distribution centers serving approximately 41 states to building materials dealers, national buying groups, home centers, and industrial users comprising makers of manufactured homes. Huttig Building Products, Inc. was founded in 1865 and is headquartered in St. Louis, Missouri.
Resverlogix logo

Resverlogix

TSE:RVX
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.